A prospective ‘PARP inhibitor’ drug that has struggled to show effectiveness in clinical trials against cancers can be structurally modified to greatly increase its power to kill tumor cells, researchers from Penn Medicine report this week in Science.
- Microplastic pollution harms lobster larvae, study finds
- Repurposing public health systems to decode COVID-19
- Measuring tape is a critical tool for following Zika virus-exposed children
- Mental health benefits of parks dimmed by safety concerns
- Nematode has potential to reduce cotton yields by 50 percent